JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 1991; 18:1602-1609
© 1991 by the American College of Cardiology Foundation
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Davies, R.
Right arrow Articles by Klinke, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Davies, R.
Right arrow Articles by Klinke, W.

Enalapril versus digoxin in patients with congestive heart failure: a multicenter study. Canadian Enalapril Versus Digoxin Study Group

RF Davies, DS Beanlands, C Nadeau, D Phaneuf, A Morris, JM Arnold, JO Parker, R Baigrie, P Latour, WP Klinke, et al.

Division of Cardiology, University of Ottawa Heart Institute, Ontario, Canada.

Patients with New York Heart Association functional class II or III heart failure stabilized on furosemide therapy were entered into a randomized controlled trial comparing enalapril (n = 72) and digoxin (n = 73). End points were clinical outcome, treadmill exercise capacity and echocardiographic left ventricular dimensions. Improvement in clinical outcome was defined as a reduction of at least one functional class or withdrawal because of an adverse clinical event. After 4 weeks, 13 patients receiving enalapril showed improvement, 55 had no change and 9 manifested deterioration compared with 7, 49 and 17, respectively, in the digoxin group (p less than 0.01). After 14 weeks, 13 patients receiving enalapril showed improvement, 50 had no change and 9 manifested deterioration, compared with 14, 37 and 22, respectively, in the digoxin group (p less than 0.025). More patients in the digoxin group were withdrawn because of an adverse clinical event (p less than 0.05). Exercise time and percent fractional shortening improved in both groups (p less than 0.001 and less than 0.05, respectively), with no significant difference between groups (p greater than 0.50). Both rate-pressure product and subjectively evaluated exertion during submaximal exercise were reduced only in the enalapril group. Although the majority of patients in both groups did well, those receiving enalapril experienced fewer adverse clinical events and had less fatigue during submaximal exercise.


This article has been cited by other articles:


Home page
 CirculationHome page
S. H. Rahimtoola
Digitalis Therapy for Patients in Clinical Heart Failure
Circulation, June 22, 2004; 109(24): 2942 - 2946.
[Full Text] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
J. T. Sullebarger, P. M. D'Ambra, L. C. Clark, L. Thanikarry, and H. L. Fontanet
Effect of Digoxin on Ventricular Remodeling and Responsiveness of {beta}-Adrenoceptors in Chronic Volume Overload
Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1998; 3(4): 281 - 290.
[Abstract] [PDF]

Home page
 NEJMHome page
M. Packer, M. Gheorghiade, J. B. Young, P. J. Costantini, K. F. Adams, R. J. Cody, L. K. Smith, L. Van Voorhees, L. A. Gourley, M. K. Jolly, et al.
Withdrawal of Digoxin from Patients with Chronic Heart Failure Treated with Angiotensin-Converting-Enzyme Inhibitors
N. Engl. J. Med., July 1, 1993; 329(1): 1 - 7.
[Abstract] [Full Text]

Home page
 JWatch GeneralHome page
ENALAPRIL VERSUS DIGOXIN FOR HEART FAILURE
Journal Watch (General), December 17, 1991; 1991(1217): 3 - 3.
[Full Text]


HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 1991 by the American College of Cardiology Foundation.